A portion of a state law in Oregon that required pharmaceutical companies to report on price increases has been suspended. This decision came after a U.S. District Court judge ruled in favor of a pharmaceutical industry trade group that argued the reporting requirements were unconstitutional. The industry group contended that disclosing information about marketing and research spending for drugs that experienced price hikes would reveal trade secrets. The transparency law was enacted in 2018 as a way to hold the pharmaceutical industry accountable for price hikes that were straining budgets. The suspension of this reporting requirement is seen as a victory for the pharmaceutical industry.
Source link
Oregon suspends part of its drug transparency law called unconstitutional
